Want to see NGEN full AI Analyst Report?
NGEN Stock Chart & Stats
$2.21
$0.00(0.00%)
At close: 4:00 PM EST
$2.21
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.58 - $6.30
Previous CloseN/A
VolumeN/A
Average Volume (3M)552.18K
Market Cap
$220.42M
Enterprise Value$129.26
Total Cash (Recent Filing)$86.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 12, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding107,522,640
10 Day Avg. Volume504,681
30 Day Avg. Volume552,184
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)159.85
Price to Sales (P/S)0.00
P/FCF Ratio-28.50
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside465.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageNear-zero debt limits mandatory interest and principal payments, preserving flexibility while NervGen funds clinical development. This gives the company a stronger balance-sheet position than a similarly unprofitable biotech carrying substantial leverage, although it does not remove its need for capital.
Improved Capitalization And LiquidityThe sharp increase in cash and assets strengthens NervGen’s ability to continue trials and corporate operations over the coming quarters. A larger liquidity cushion can reduce immediate financing pressure and provide more time to advance NVG-291 development before additional funding is required.
Focused Clinical PipelineA lead program aimed at nervous-system repair gives NervGen a focused development strategy and potential applicability across multiple neurological indications. If clinical development supports the candidate’s potential, this breadth could expand partnering or commercialization opportunities beyond a single use case.
Bears Say
No Commercial RevenueNervGen currently lacks recurring product revenue to fund research, trials, or corporate expenses. Until a candidate is approved and commercialized, the business remains dependent on financing, licensing, or collaboration proceeds, making progress vulnerable to development outcomes and capital availability.
Widening Losses And Cash BurnEscalating losses and increasingly negative operating cash flow show that spending is rising faster than any internally generated funding. Persistent burn will require continued access to external capital and may constrain the pace of development or force less favorable financing decisions.
Shareholder Dilution ExposureThe ATM facility provides funding flexibility but creates a direct route to dilution as shares are issued. The enlarged warrant liability adds financial complexity and potential volatility, while repeated equity financing can reduce existing holders’ ownership as the clinical program consumes cash.
NervGen Pharma News
NGEN FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was $1.58 and its highest was $6.30 in the past 12 months.
What is NervGen Pharma’s market cap?
NervGen Pharma’s market cap is $220.42M.
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Nov 12, 2026 which is in 53 days.
How were NervGen Pharma’s earnings last quarter?
NervGen Pharma released its earnings results on Aug 13, 2026. The company reported -$0.265 earnings per share for the quarter, missing the consensus estimate of -$0.061 by -$0.204.
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -0.1.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 107,522,640 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
NervGen Pharma reported an EPS of -$0.265 in its last earnings report, missing expectations of -$0.061. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in NGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NervGen Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (465.61% Upside)
$12.50 (465.61% Upside)
Blogger Sentiment
Bullish
NGEN Sentiment 100%
Sector Average 63%
Sector Average 63%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 13.7%
Last 30 Days ▼ 13.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
412.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NervGen Pharma
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
NGEN Stock 12 Month Forecast
Average Price Target
$12.50
▲(465.61% Upside)
Technical Analysis
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―
Ownership Overview
15.65% Insiders
8.67% Other Institutional Investors
75.68% Public Companies and
Individual Investors